Cargando…
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910084/ https://www.ncbi.nlm.nih.gov/pubmed/36776363 http://dx.doi.org/10.3389/fonc.2022.1085270 |
_version_ | 1784884713705439232 |
---|---|
author | Aaltonen, Kristina Radke, Katarzyna Adamska, Aleksandra Seger, Alexandra Mañas, Adriana Bexell, Daniel |
author_facet | Aaltonen, Kristina Radke, Katarzyna Adamska, Aleksandra Seger, Alexandra Mañas, Adriana Bexell, Daniel |
author_sort | Aaltonen, Kristina |
collection | PubMed |
description | Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in vitro cultures. These models can be used to decipher mechanisms of metastasis and treatment resistance, for drug screening, and preclinical drug testing. Patient-derived neuroblastoma models may also provide useful information about clonal evolution, phenotypic plasticity, and cell states in relation to neuroblastoma progression. We summarize current opportunities for, but also barriers to, future model development and application. Integration of patient-derived models with patient data holds promise for the development of precision medicine treatment strategies for children with high-risk neuroblastoma. |
format | Online Article Text |
id | pubmed-9910084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99100842023-02-10 Patient-derived models: Advanced tools for precision medicine in neuroblastoma Aaltonen, Kristina Radke, Katarzyna Adamska, Aleksandra Seger, Alexandra Mañas, Adriana Bexell, Daniel Front Oncol Oncology Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic models of neuroblastoma that closely resemble the human disease to further interrogate underlying mechanisms and to develop novel therapeutic strategies. Here we review recent developments in patient-derived neuroblastoma xenograft models and in vitro cultures. These models can be used to decipher mechanisms of metastasis and treatment resistance, for drug screening, and preclinical drug testing. Patient-derived neuroblastoma models may also provide useful information about clonal evolution, phenotypic plasticity, and cell states in relation to neuroblastoma progression. We summarize current opportunities for, but also barriers to, future model development and application. Integration of patient-derived models with patient data holds promise for the development of precision medicine treatment strategies for children with high-risk neuroblastoma. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9910084/ /pubmed/36776363 http://dx.doi.org/10.3389/fonc.2022.1085270 Text en Copyright © 2023 Aaltonen, Radke, Adamska, Seger, Mañas and Bexell https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Aaltonen, Kristina Radke, Katarzyna Adamska, Aleksandra Seger, Alexandra Mañas, Adriana Bexell, Daniel Patient-derived models: Advanced tools for precision medicine in neuroblastoma |
title | Patient-derived models: Advanced tools for precision medicine in neuroblastoma |
title_full | Patient-derived models: Advanced tools for precision medicine in neuroblastoma |
title_fullStr | Patient-derived models: Advanced tools for precision medicine in neuroblastoma |
title_full_unstemmed | Patient-derived models: Advanced tools for precision medicine in neuroblastoma |
title_short | Patient-derived models: Advanced tools for precision medicine in neuroblastoma |
title_sort | patient-derived models: advanced tools for precision medicine in neuroblastoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910084/ https://www.ncbi.nlm.nih.gov/pubmed/36776363 http://dx.doi.org/10.3389/fonc.2022.1085270 |
work_keys_str_mv | AT aaltonenkristina patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma AT radkekatarzyna patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma AT adamskaaleksandra patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma AT segeralexandra patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma AT manasadriana patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma AT bexelldaniel patientderivedmodelsadvancedtoolsforprecisionmedicineinneuroblastoma |